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ABSTRACT
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splices the remaining 5' and 3' ends of the RNA back

together (the trans-excision-splicing reaction) is disclosed.
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TRANS-EXCISION-SPLICING RIBOZYME
AND METHODS OF USE

A catalytic RNA that can excise a speci?c RNA sequence

out of a larger RNA (the trans-excision-splicing reaction),
although not previously discovered or engineered, Would be

This application claims priority to Provisional Applica

very useful as a biochemical tool and also as a potential neW

therapeutic strategy. For example, multiple turnover cata
lytic RNAs, or riboZymes, With this activity could be used to

tion Ser. No. 60/431,965, ?led Dec. 10, 2002.
FIELD OF THE INVENTION

excise a disease-causing RNA region out of a native tran
script, to remove a premature stop codon, or to restore a

This invention relates generally to the ?eld of genetic
therapeutics. More particularly, the invention relates to a

frameshift mutation, for example.

trans-excision-splicing riboZyme having adaptable sequence

SUMMARY OF THE INVENTION

recognition speci?city that provides a poWerful tool for

genetic therapies.

In one aspect of the invention there is provided a trans

excision-splicing riboZyme comprising at least tWo recog
BACKGROUND OF THE INVENTION

nition elements that are complementary to a target sequence
Within a substrate, Wherein the target sequence is not

The discovery of catalytic RNA fundamentally changed
the course of science. The subsequent realiZation that cata
lytic RNAs could be tailored to suit individual needs has

been nothing less than inspiring. Indeed, the past ten years

20

has seen the creative development of numerous RNA cata

lysts. Concurrently, the diversity of applications for these
catalytic RNAs has been escalating. For example, catalytic

of the substrate created by the excision to an 00G of the 3' end

of the substrate created by the excision.
In another aspect of the invention there is provided a

RNAs are being developed for detection protocols, for
therapeutic intervention of diseases, and for use as bio
chemical tools. As We continue to exploit the steadily

25

the cassette comprising a promoter operably-linked to a

nucleotide sequence encoding a trans-excision-splicing
riboZyme comprising at least tWo recognition elements that
30

activity, Which enables the riboZyme to repeatedly cleave
other separate RNA molecules in a nucleotide base
sequence-speci?c manner. Such enZymatic RNA molecules
can be targeted to virtually any RNA transcript, and ef?cient
cleavage achieved in vitro. Kim et al., 84 Proc. Natl. Acad.
Sci. USA 8788, 1987; Haselolf and Gerlach, 334 Nature

are complementary to target sequence Within a substrate

other than that complementary to native recognition ele
ments, Wherein at least one of said recognition elements
stabiliZes binding of the riboZyme to a trans-excision splic
35

ing (TES) reaction intermediate product and Wherein the
riboZyme catalyZes a speci?c excision of the target sequence
and splices the 5' end of the substrate created by the excision
to an 00G of the 3' end of the substrate created by the
excision.

585, 1988; Cech, 260 JAMA 3030, 1988; and Je?‘eries et al.,
17 Nucleic Acids Research 1371, 1989.
RiboZymes act by ?rst binding to a target RNA. Such
binding occurs through the target RNA binding portion of a
riboZyme, Which is held in close proximity to an enZymatic
portion of the RNA that acts to cleave the target RNA. Thus,
the riboZyme ?rst recogniZes and then binds a target RNA
through complementary base-pairing, and once bound to the
correct site, acts enZymatically to cut the target RNA.

polynucleotide molecule comprising a riboZyme expression
cassette that is capable of being stably inserted into a host,

increasing knowledge base of RNA structure, folding, and
catalysis, designing and applying novel and e?‘ective RNA
catalysts is becoming more and more tractable.
RiboZymes are RNA molecules having an enZymatic

complementary to native recognition elements, Wherein at
least one of said recognition elements stabiliZes binding of
the riboZyme to a trans-excision splicing (TES) reaction
intermediate product, and Wherein the riboZyme catalyZes a
speci?c excision of the target sequence and splices the 5' end

40

Also provided are host cells transfected With the poly
nucleotide molecule.
In yet another aspect of the invention there is provided a
method for in vitro trans-splicing-excison of a target

sequence, comprising the steps of:
(1) providing the riboZyme of the invention in a trans
45

splicing reaction mixture;
(2) providing a substrate comprising the target sequence

Strategic cleavage of such a target RNA destroys its ability

to the reaction mixture; and

to direct synthesis of an encoded protein. After a riboZyme
has bound and cleaved its RNA target it is released from that
RNA to search for another target and can repeatedly bind

(3) catalyZing the trans-splicing-excision of the target

Six basic varieties of naturally-occurring enZymatic

sequence.
In another aspect of the invention there is provided a
method for deleting an undesired genetic sequence from a

RNAs are knoWn presently. Each can catalyZe the hydrolysis
of RNA phosphodiester bonds in trans (and thus can cleave

host cell in vivo, said method comprising:
(1) providing the riboZyme of the invention to the host

and cleave neW targets.

other RNA molecules) under physiological conditions. In
general, enZymatic nucleic acids act by ?rst binding to a
target RNA. Such binding occurs through the target binding
portion of an enZymatic nucleic acid Which is held in close
proximity to an enZymatic portion of the molecule that acts
to cleave the target RNA. Thus, the enzymatic nucleic acid
?rst recogniZes and then binds a target RNA through

50

cell, said riboZyme possessing catalytic activity against a
55

the excision to an 00G of the 3' end of the substrate created

by the excision.
60

The folloWing de?nitions are used herein.

RiboZyme: An RNA molecule that inherently possesses

complementary base-pairing, and once bound to the correct

site, acts enZymatically to cut the target RNA. Strategic
cleavage of such a target RNA Will destroy its ability to
direct synthesis of an encoded protein. After an enzymatic
nucleic acid has bound and cleaved its RNA target, it is

target RNA sequence present in said host cell, Wherein the
riboZyme catalyZes a speci?c excision of the target RNA
sequence and splices the 5' end of the substrate created by

catalytic activity.
Trans-splice: A form of genetic manipulation Whereby a
65

nucleic acid sequence of a ?rst polynucleotide is colin
early linked to or inserted colinearly into the sequence of

released from that RNA to search for another target and can

a second polynucleotide, in a manner that retains the 3'-5'

repeatedly bind and cleave neW targets.

phosphodiester linkage betWeen such polynucleotides. By

US 7,211,661 B2
4

3

splicing reaction, the bridging region (White lettering) is

“directed” trans-splicing or “substrate-speci?c” trans
splicing is meant a trans-splicing reaction that requires a
speci?c specie of RNA as a substrate for the trans-splicing
reaction (that is, a speci?c specie of RNA in Which to

P9.0, and P10 are helices that result from the recognition

splice the transposed sequence). Directed trans-splicing

elements RE1, RE2, and RE3 base pairing With the sub

may target more than one RNA specie if the riboZyme is
designed to be directed against a target sequence present

strate. The large bold arroWs indicate the sites of catalysis
for the ?rst (left) and second (right) step of the trans
excision-splicing reaction. The 5' uridine and 3' guanosine

excised and the 5' and 3' regions of the substrate (black

lettering) are subsequently spliced together. Note that P1,

in a related set of RNAs.

are circled. The riboZyme bases are numbered according to

Target sequence: Anucleic acid molecule, e.g., RNA, that is
a substrate for the catalytic activity of a riboZyme of the

that for the R carinii intron (Testa, S. M., Haidaris, C. G.,

Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36,
15303*153 14.13, incorporated herein in its entirety). 2B).
Simpli?ed diagrams of various substrates base pairing With
various riboZymes. Only the recognition element sequences

invention.

Expression Cassette: A genetic sequence that provides
sequences necessary for the expression of a riboZyme of
the invention.
Stably: By “stably” inserting a sequence into a genome is

are shoWn for the riboZymes. The dashed line indicates a

functioning of the sequence (or sequences). For example,

normal phosphodiester bond betWeen the adjoining
sequences. i) The 12-mer substrate (SEQ ID NO:7) binding
to rP-8/4x (SEQ ID NO:11). ii) The 10-mer substrate (SEQ
ID NO:8) binding to rP-8/4x (SEQ ID NO:11). iii) The
38-mer Myotonic Dystrophy substrate (SEQ ID NO: 12)
binding to the rP8/4x-MD Myotonic Dystrophy riboZyme

by operably linking a riboZyme encoding sequence to a

(SEQ ID NO:13).

promoter, expression of the riboZyme encoding sequence

FIG. 3. The Trans-Excision-Splicing Reaction using the R
carinii system. The Trans-Excision-Splicing (TES) Reaction

intended insertion in a manner that results in inheritance

of such sequence in copies of such genome.

Operable linkage: An “operable linkage” is a linkage in
Which a sequence is connected to another sequence (or
sequences) in such a Way as to be capable of altering the

is placed under the in?uence or control of that promoter.
TWo nucleic acid sequences, such as a riboZyme encoding
sequence and a promoter region sequence at the 5' end of
the encoding sequence, are said to be operably linked if
induction of promoter function results in the transcription
of the riboZyme encoding sequence and if the nature of the
linkage betWeen the tWo sequences does not (1) result in
the introduction of a frame-shift mutation, (2) interfere

20

25

substrates and products of the TES reaction using 166 nM
rP-8/4x riboZyme and 1.33 nM substrate at 7 mM MgCl2

(36-mer) and 10 mM MgCl2 (10-mer and 12-mer) at 440 C.
30

NO:15). RE2, and RE3) are underlined. All reactions in the
presence (+) and absence (—) of the rP-8/4x riboZyme Were
35

Native target sequence/Non-native target sequence: Native
target sequence of a riboZyme is that polynucleotide
sequence Which is recogniZed, bound and reacted by

Wild-type (native) riboZymes. Non-native target sequence

The reaction using the 36-mer substrate is diagrammed on
the left (SEQ ID NO: 10. SEQ ID NO:14, and SEQ ID
NO:15). The regions of the substrate that bind to the

ribozyme’s recognition elements (labeled RE1 (SEQ ID

With the ability of the expression regulatory sequences to
direct the expression of the riboZyme. Thus, a promoter
region Would be operably linked to a nucleic acid
sequence if the promoter Were capable of e?fecting the
synthesis of that nucleic acid sequence.

Using the R carinii System. A) Polyacrylamide gel shoWing

subjected to the same incubation conditions. TES reactions
Were conducted using a 36-mer substrate (to give a 16-mer
product), a 12-mer substrate (9-mer product), and a 10-mer

substrate (9-mer product). See FIG. 2 for the sequence of
40

these substrates. The 6-mer lane shoWs a synthetic control
for the 5' cleavage products, the 16-mer lane shoWs a

synthetic control for the 16-mer TES product, and the “OH
lane shoWs an alkaline digest of the 36-mer starting material.

is sequence Within a substrate that is not bound by Wild

type riboZyme and consequently native riboZyme does not
react With non-native target sequence. Non-native target

B). Graphs of TES reactions using the 36-mer substrate. All

sequence can occur as a result of mutation, for example.

reactions Were run as above except for the changing vari
45

BRIEF DESCRIPTION OF THE DRAWINGS

able. The TES product is represented by ?lled circles and the

5' cleavage product by open circles. C). Graphs of TES
reactions using the 10-mer substrate. All reactions Were run

FIG. 1. The Group I Intron Self-Splicing (1a: left) and

as above except for the changing variable. The TES product

Trans-Excision-Splicing Reactions (lb: right). The catalytic

is represented by ?lled triangles and the 5' cleavage product

RNAs are represented by gray lines, the 5' and 3' exons and
mimics are black lines, and the bridge (excised region) is a

50

independent assays.
FIG. 4. Sequencing of Trans-Excision-Splicing Products.

dotted line. The circle in the 5' exon represents a uridine and
the circle in the 3' exon represents a guanosine. The intron

inherently contains all the required activities for the trans
excision-splicing reaction. RE1, RE2, and RE3 are three
recognition elements that the catalytic RNAs may use to
base pair With their substrates (RE1 is also referred to as the
IGS, or Internal Guide Sequence.). It is likely that RE2

55

and/or RE3 do not bind the substrate until after the ?rst
60

riboZyme, rP-8/4x (uppercase lettering. SEQ ID NO:9),

65

gray background, SEQ ID NO:10). In the trans-excision

For each system, a chemically synthesiZed version of the
expected product Was sequenced and run adjacent to the
isolated excision product. Left: the R carinii 16-mer product
that results from treating the 36-mer substrate With the

rP-8/4x riboZyme. Right: the Myotonic Dystrophy 10-mer

reaction step. In addition, at least With the rP-8/4x riboZyme
used herein, the guanosine cofactor is not required for
initiation of the ?rst catalytic step.
FIG. 2. The rP-8/4x and rP-8/4x-MD RiboZymes Base
Pairing With Various Substrates. 2A) The R carinii
binding to the 36-mer substrate (loWercase lettering With a

by open triangles. Each graph shoWs the average of tWo

product that results from treating the 38-mer substrate With
the rP-8/4x-MD riboZyme. The dotted line represents the
neWly created splice junction betWeen the 5' and 3' ends of
the substrate. Nuclease T1 is speci?c for guanosine, U2 for
adenosine, and CL-3 primarily for cytidine. The “OH lane
shoWs an alkaline digest of the starting material, and the
lanes labeled ‘Start’ shoW the starting material.
FIG. 5. Competition TES Reactions. Polyacrylamide gel
shoWing substrates and products of TES reactions using 166
nM rP-8/4x, 7 mM MgCl2, and 440 C. ‘Radiolabeled sub

US 7,211,661 B2
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strate’ refers to the length of the radiolabeled substrate at
1.33 nM ?nal concentration and ‘cold substrate’ refers to the
length of the non-radiolabeled substrate. The ?nal concen
trations of the cold substrates are 1.33 nM for the 36-mer,
and 66.5 nM (50><) or 665 nM (500><) for the 7-mer, Which

has the ability to bind and catalyZe reactions using exog
enous substrates that contain 5' and 3' exon sequences (Zaug,

A. J. & Cech, T. R. (1986) Science 231, 4704475.). Ifthe 5'
and 3' exon sequences are connected With a bridging

sequence and recognition elements are maintained, this
riboZyme can excise the bridging sequence and splice the 5'
and 3' ends of the substrate together. A simple diagram of
this trans-excision-splicing reaction is shoWn in FIG. 1b.
This reaction Was tested using a riboZyme, rP-8/ 4x, from the
opportunistic pathogen Pneumocyslis carinii. In FIG. 2A it
is shoWn that this riboZyme catalyZes the trans-excision
splicing reaction using a synthetic substrate Which is
complementary to the native recognition elements of the

is r(GUGCUCU) (SEQ ID NO:16). The tWo substrates for
each reaction Were added simultaneously. Lanes designated
in the ?rst box are length controls, the second box shoWs the
5' exon competition assay, the third box shoWs an alkaline

digest of the 36-mer starting material, and the fourth box
shoWs the 3' exon competition assay.
FIG. 6. The TES Reaction Using the DMPK Model

System. A) Polyacrylamide gel shoWing substrates and
products of the TES reaction using 166 nM rP-8/4x-MD
riboZyme, 1.33 nM substrate, 13 mM MgCl2, and 440 C. The
reaction using the 38-mer DMPK mimic is diagrammed on
the left (SEQ ID NO: 12. SEQ ID NO:17 and SEQ ID
NO:18). The regions of the substrate that bind to the
riboZyme’s recognition elements are labeled RE1 (SEQ ID
NO: 18), RE2, and RE3. All reactions in the presence (+) and
absence (—) of the rP-8/4x-MD riboZyme Were subjected to

rP-8/4x riboZyme. Moreover, as little as a single nucleotide
can be excised.

In order for this reaction to be useful, hoWever, the
riboZyme recognition elements have to be mutable, such that
the riboZyme can be targeted to bind With and react on
non-native sequences. Using a group I intron-derived
20

RE1 (also referred to as the IGS, or Internal Guide

Sequence) Was mutated and the resultant riboZyme then
bound to a neW, complementary substrate (Murphy, F. L. &

the same incubation conditions. TES reactions Were con

ducted using the 38-mer substrate (to give a 10-mer prod
uct). The 6-mer lane shoWs a synthetic control for the 5'
cleavage products, the 10-mer lane shoWs a synthetic control
for the 10-mer TES product, and the ‘OH lane shoWs an
alkaline digest of the 38-mer starting material. The lanes
labeled 36 are TES reactions using the rP-8/4x-MD
riboZyme With the 36-mer R carinii substrate (at 13 mM

MgCl2), and the lane labeled 38 (lane 0) is a reaction using
the rP-8/4x riboZyme With the 38-mer DMPK mimic (at 7
mM MgCl2). In these cases, no reaction occurs. B). Graphs
of TES reactions using the 38-mer substrate and rP-8/4x

25

that can replace the 3' end of mutant transcripts With
30

corrected versions (Sullenger, B. A. & Cech, T. R. (1994)

Nature 371, 61946; Lan, N., HoWrey, R. R, Lee, S. W.,
Smith, C. A., & Sullenger, B. A. (1998) Science 280,

159341596).
Trans-excision-splicing riboZymes are ideal for treating

variable. The TES product is represented by ?lled squares
and the 5' cleavage product by open squares.
FIG. 7. TES reactions using tWo different Telrahymena
riboZymes. FIG. 7A is a polyacrylamide gel shoWing sub
strates, intermediates, and products of the TES reaction. The

35

reaction Was carried out for 90 minutes using 166 nM
riboZyme and 1.33 nM radiolabeled 13-mer substrate at
either 0 mM or 10 mM MgCl2 at 44 degrees C, either in the
presence (+) or absence (—) of 330 nM GMP. FIG. B is a

40

genetic diseases for Which the causative affects may be
ameliorated by the excision of an internal RNA segment out

of a larger RNA, including triplet-expansion diseases such

as Huntington’s disease, Fragile X, and Myotonic Dystrophy
(BoWater, R. P. & Wells, R. D. (2001) Prog. Nucleic Acid
Res. Mol. Biol. 66, 1594202). Patients affected with these
diseases have an RNA that is present in normal individuals,
except that embedded Within it is an abnormally high
number of tandem repeat sequences. For Myotonic Dystro

phy, the expansion is in the 3' llnIranslated Region [3' UTR]
45

menu). The TES product is represented by the ?lled circles
and the 5' intermediate (CUCUCU) (SEQ ID NO:21) is
represented by open circles. All reactions Were run as above

Cech, T. R. (1989) Proc. Natl. Acad. Sci. USA. 86,
921849222; Been, M. D. & Cech, T. R. (1986) Cell 47,

2074216; Zaug, A. 1., Been, M. D., & Cech, T. R. (1986)
Nature 324, 4294433). This property has been exploited for,
among other purposes, designing trans-splicing riboZymes

MD. All reactions Were run as above except for the changing

diagram of the TES reaction (SEQ ID NO:19 and SEQ ID
NO:20). The excised G of SEQ ID NO:19 is in bold
lettering. FIG. 7C shoWs tWo graphs of TES reactions using
the 13-mer substrate and the A-L-21 Sca riboZyme (Telrahy

riboZyme from Telrahymena lhermophila, the sequence of

of a serine-threonine protein kinase gene [the DMPK gene],
Whose expression induces the expression of skeletal muscle
speci?c genes. The disease state of Myotonic Dystrophy,
Which is the most common form of adult onset Muscular

50

except for the changing variable. Each curve represents the
average of tWo independent assays. Standard deviation for
all points Was less than 10%. For clarity the graphs use
different scales.

Dystrophy, typically has much more than 35 CUG repeats,
While una?fected individuals typically have less than 15
repeats. The greater the number of repeats, the more severe

the affects of the disease. Moreover, strong experimental
evidence indicates the disease stems directly from the RNA
repeats, and not to any a?fected coding potential of the parent
55

DETAILED DESCRIPTION OF THE
INVENTION

DNA. In fact, the Myotonic Dystrophy triplet-expansion and
recently discovered quadruplet-expansion diseases have the
repeat sequences Within non-coding regions, so their effects
are not due to the synthesis of mutant proteins. A neW class

The inherent binding and catalytic activity of group I
intron-derived riboZymes can be exploited to catalyZe the

60

trans-excision-splicing reaction. FIG. 1a shoWs a simple

diagram of a typical group I intron-catalyZed self-splicing

diseases.
The rP-8/4x riboZyme Was re-engineered to test the poten

reaction. There are three base pairing contacts that the intron
uses to hold and position its 5' and 3' exons for subsequent

catalysis. We have termed these the riboZyme recognition
elements, or RE1, RE2, and RE3. Physically removing the
intramolecular exons from the intron creates a riboZyme that

of riboZymes that can speci?cally excise these expanded
RNA repeats from the transcripts could aid in the develop
ment of much needed therapeutics against these types of
tial to alter the sequence speci?city of trans-excision-splic

65

ing riboZymes to bind and excise the triplet expansion region
from a Myotonic Dystrophy DMPK small model system in

vitro. The resultant riboZyme excises the triplet expansion
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region, and in a sequence speci?c manner. That trans

for this, including the longer bridge of the 36-mer substrate
partially interfering With the substrate’s ability to bind the
recognition elements.

excision-splicing ribozymes can be re-engineered to target
and act upon predetermined sequences demonstrates a gen
eral usefulness for these ribozymes as biochemical tools and

The sequence speci?city of the R carinii ribozyme can be
altered. Altering the recognition elements of the R carinii
ribozyme changes the sequence speci?city of the trans

therapeutics .

R carinii group I intron ribozyme catalyzes the trans

excision-splicing reaction. While it Was knoWn that RE1

excision-splicing reaction.

could be modi?ed in reactions mimicking the ?rst step of the
self-splicing reaction, it Was previously not knoWn that all
three elements are mutable. That these recognition elements

A ribozyme derived from a R carinii group I intron

catalyzes a previously unreported excision-splicing reaction
on an exogenous substrate. This trans-excision-splicing

completely specify binding and reactivity indicates that they

reaction takes advantage of the catalytic abilities of this

are the primary determinants of speci?city betWeen the

ribozyme. First, rapid and ef?cient sequence-speci?c cleav

ribozyme and its substrate. In addition, bridging regions of
different sequences and lengths (1, 3, 20, and 28 nucleotides)
have been excised, indicating that the 3' G in the bridging
region might be the only potential sequence requirement for

age of a designated substrate occurs in a guanosine inde

pendent fashion, as previously reported (Testa, S. M., Hai
daris, C. G., Gigliotti, F., & Turner, D. H. (1997)
Biochemistry 36, 15303*15314.). Second, the resultant 5'

the excised segment. Structure might even be tolerated
Within the excised region, as the someWhat structured CUG

cleavage product can splice to a sequence that binds the 3'

end of the ribozyme (Inoue, T., Sullivan, F. X., & Cech, T.
R. (1985) Cell 43, 431*437) (FIG. 1B). These activities Were
exploited by designing a synthetic substrate that contains
Within it the sequences required for each catalytic event,
separated by an internal bridging sequence (FIG. 2A). As
seen in FIG. 3, the engineered ribozyme catalyzes the
speci?c excision of the bridge sequence and splices the 5'
and 3' ends of the substrate back together. Even though there

repeat Within the Myotonic Dystrophy substrate doesn’t
prohibit the reaction. In addition, each ribozyme only acts
upon its designated target, even though the RBIs in both
ribozymes are 50% identical, giving a further indication of
the high level of sequence speci?city of this reaction.
25

Although the MgCl2 concentration required for maximum
activity is di?cerent for the tWo ribozymes (7 and 13 mM),

30

they both are active throughout the same general MgCl2
concentration range (data not shoWn), Which is beloW that
required (15 mM) for maximum activity for the R carinii
group I intron self-splicing reaction in vitro.
The ability to catalyze TES reactions is inherent to Group

are 18 other uridines that could be sites of 5' cleavage and

4 other guanines that could be sites of 3' splicing, only one

trans-excision-splicing product is generated. Apparently, the
ribozyme recognition elements that de?ne the individual
catalytic steps are sequence speci?c.
That the ribozyme can catalyze this reaction is surprising

I introns. To determine Whether other ribozymes can cata

lyze TES reaction, a Tetrahymena icontaining L-21 ScaI
plasmid Was linerarized With ScaI, run-01f transcriptions

in that the relatively long bridging region could be expected
to sterically hinder the binding of the substrate to the
catalytic core of the ribozyme or hinder the required con
formational rearrangement betWeen the tWo catalytic steps

(Cech, T. R., Herschlag, D., Piccirilli, J. A., & Pyle, A. M.
(1992) J. Biol. Chem. 267, l7479il7482; and 39. Jaeger, L.,
Michel, F. & Westhof, E. (1996) in Catalytic RNA, eds.
Eckstein, F. & Lilley, D. (Heidelberg, Germany), Vol. 10, pp.

Were performed, and the ribozyme Was puri?ed as described
35

reactions Were run in a variety of standard buffers and

conditions routinely used for ribozyme reactions. The reac
tions Were also run in the presence and absence of the PG
cofactor. In all cases, the ?rst step of the reaction Was the
40

1*17). Perhaps this accounts for over 50% of the substrate

addition, like other ribozymes, the P. carinii ribozyme binds
its 5' exon sequences orders of magnitude tighter than its 3'
45

prior to the second catalytic step. Nevertheless, a signi?cant
amount of trans-excision-splicing product is generated.
could ligate to the 3' exon of another substrate. Since
50

the expected TES product. These results demonstrate that
the the ability to catalyze TES reactions is a general property

nism occurs to a signi?cant extent.
55

inherent to group I introns.

60

Comparison With the Trans-Splicing Reaction. The trans
excision-splicing reaction of the invention is fundamentally
different from the trans-splicing reaction previously reported
(Sullenger, B. A. & Cech, T. R. (1994) Nature 371,
619*622.), Whereby a ribozyme covalently attached to a

otide. The R carinii ribozyme excises as little as a single

nucleotide, and in a sequence-speci?c manner. Apparently,
there is no loWer limit to the size of the region being excised.
That the same approximate yield is obtained regardless of
Whether the 12-mer (39%) and 10-mer (36%) substrate is
used suggests that the role of forming the P90 helix is not
large in this case, as the 10-mer lacks the ability to form the

normal RNA sequence binds to a mutant RNA transcript,

cleaves the mutant transcript, and replaces the 3' end of the
mutant transcript With the normal ‘corrected’ version. While
trans-splicing can correct mutant RNA, it is single-tumover,

P90 helix. Therefore, the RE2 interaction, although perhaps
bene?cial, is not required to establish a sequence speci?c
interaction. In addition, the 12-mer and 10-mer substrates
lead to approximately 50% more product as compared With
the 36-mer substrate. There are many possible explanations

ribozyme generates a product band of the expected size (a
12-mer product from a 13-mer substrate). The product band
Was excised from the band and sequenced, and shoWn to be

catalytic event) is produced, it is unlikely that this mecha
The R carinii ribozyme can excise as little as one nucle

tion results in signi?cantly reduced second-step yields.
Therefore, the Telrahymena ribozyme Was modi?ed to con
tain an RE3 region in order to stabilize binding of the
ribozyme to the ’3 exon reaction intermediate. The results
are shoWn in FIG. 6. The reaction using the stabilized

Another consideration is that the 5' exon of one substrate

spontaneous 3' splice site hydrolysis is essentially non
existent and only an insigni?cant amount of 5' exon-bridge
26-mer product (Which Would be a side reaction of this

only reaction step that Was detected.

The lack of a full-length, second-step reaction product
suggests that the second step may be inef?cient or problem
atic With this ribozyme. Our previous studies of the R carinii
ribozyme had demonstrated that 3' intermediate disassocia

only undergoing the ?rst catalytic step (see FIG. 3). In
exon sequences, Which alloWs time for 3' end dissociation

by Testa et al. (Biochemistry, (1997) 36:15303*15314). TES

65

it exploits only the RBI molecular interaction, and the
ribozyme must be covalently attached to the neW, corrected

transcript. In contrast, the trans-excision-splicing reaction is
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potentially multiple turnover; it exploits the RBI, RE2,

trans-excision-splicing riboZymes are a neW class of

and/ or RE3 molecular interactions; and it excises an internal

riboZymes that permits potential biochemical and therapeu

segment from Within a larger RNA. Nevertheless, these tWo
complementary reactions share many similarities and so the

tic strategies not before possible.

Wealth of knowledge already reported for the trans-splicing

expressed in a host cell. Transcription of the riboZyme of the

The riboZymes of the invention can be introduced into and

reaction is applicable to the trans-excision-splicing reaction.

invention in a host cell occurs after introduction of the

Implications for Myotonic Dystrophy. The rP-8/4x

riboZyme gene into the host cell. If the stable retention of the

riboZyme can be redesigned to speci?cally excise the entire

riboZyme by the host cell is not desired, the riboZyme may
be chemically or enZymatically synthesized and provided to
the host cell by mechanical methods, such as microinjection,

triplet expansion region of a mimic of the Myotonic Dys
trophy transcript, implicating such riboZymes as neW types
of potential Muscular Dystrophy therapeutics. As a practical

liposome-mediated transfection, electroporation, calcium
phosphate precipitation, or the like. Alternatively, When
stable retention of the gene encoding the riboZyme is
desired, such retention may be achieved by stably inserting

matter, cutting out this entire region may or may not restore
proper function to the transcript, as normal individuals

typically have at least 5 repeats. Similar multiple turnover
riboZymes, hoWever, can be designed to target the repeats

at least one DNA copy of the riboZyme into the host’s

themselves to successively reduce expansion lengths.
General Therapeutic Implications. Unfortunately, nature

chromosome, or by providing a DNA copy of the riboZyme
on a plasmid that is stably retained by the host cell. Pref
erably the riboZyme of the invention is inserted into the
host’s chromosome as part of an expression cassette, Which

has a?‘orded a huge number of RNA-mediated mutations

that predispose individuals to disease. NeW therapeutic
strategies to combat these diseases are needed. That the
recognition elements of the rP-8/4x riboZyme can be modi
?ed and the siZe and sequence of the excised region do not
appear to have limitations suggest that trans-excision-splic

ing riboZymes may be generally useful as therapeutics
against many such diseases. For example, excising speci?c

20

25

been stably inserted into a host’s chromosome is controlled

a?fect transcription and translation regulation.
Trans-excision-splicing riboZymes are thought to have
30

cleavage site (although a cytidine might also Work) and the
second is a guanosine at the 3' splice site (FIG. 2A).
Therefore, there are three simple targeting strategies to
consider. First, a riboZyme can be designed that targets a
uridine 5' to any particular mutation and a guanosine 3' to
this mutation, as is the case in the Myotonic Dystrophy
model system described here. It should be noted that if more
than an insertion mutation is excised the neW transcript
might not function normally. Second, a mutation that results
in a neW guanosine can be targeted as the 3' splice site. The

cells. A promoter is composed of discrete modules that direct
the transcriptional activation and/or repression of the pro
35
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in most eukaryotic host cells should be selected, such as a

45

a glycolytic gene. If it is desired to express the riboZyme
only in a certain cell or tissue type, a cell-speci?c (or

tissue-speci?c) promoter element that is functional only in

involve a neW uridine (all termination codons begin With

that cell or tissue type should be selected.

uridine), hundreds of distinct mutations could be speci?cally
50

hoWever, should be considered a potential treatment rather
than a potential cure, as mutant RNA transcripts Will con
55

The trans-splicing reaction is chemically the same
Whether it is performed in vitro or in vivo. HoWever, in vivo,
the presence of the target and the riboZyme Will suf?ce to
result in trans-splicing, since cofactors are usually already
present in the host cell.

It has been previously reported that, at high MgCl2
(l0*l00 mM) and temperature (550 C. to 650 C.), Telrahy
menu group I intron riboZymes that lack both of the exons
and the IGS can catalyZe a guanosine cofactor-mediated

TES-like reaction upon binding pseudoknot structured sub
60

importance. The reactions themselves appear highly

strates, Which creates the in trans equivalent of the P1 and
P10 helices (P9.0 helix formation Was not required). The

riboZymes target and bind these pseudoknot structures
entirely through tertiary interactions. In contrast, the

sequence speci?c and as little as a single nucleotide can be

excised.

or III speci?city. If it is desired to express the riboZyme in
a Wide variety of eukaryotic host cells, a promoter functional
rRNA or a tRNA promoter, or the promoter for a Widely
expressed mRNA such as the promoter for an actin gene, or

uridine can be targeted as the 5' cleavage site. This resultant

tinue to be produced.
As shoWn herein, group I intron-derived riboZymes
obtained from different organisms can catalyZe this neW
trans-excision-splicing reaction. In addition, the sequence of
the riboZyme can be easily manipulated such that it targets
and acts upon desired substrates, including those of medical

moter in the host cell. Such modules may be mixed and
matched in the riboZyme’s promoter so as to provide for the

proper expression of the riboZyme in the host. A eukaryotic
promoter may be any promoter functional in eukaryotic
cells, and especially may be any of an RNA polymerase I, II

be designed With care. Third, a mutation that results in a neW

targeted. Therefore, many options for targeting are possible,
Which expands the potential usefulness of these riboZymes.
The general strategy of targeting mutations at the RNAlevel,

by the promoter sequence that is operably linked to the
riboZyme coding sequences. The promoter that directs
expression of the riboZyme may be any promoter functional
in the host cell, prokaryotic promoters being desired in

prokaryotic cells and eukaryotic promoters in eukaryotic

above strategies Will also target normal transcripts for at
least the ?rst step of the reaction, so these strategies should
riboZyme Would not attack the normal transcript, but Would
perform both steps on the mutant transcript. Since point
mutations that result in premature termination codons often

element, an enhancer or UAS element, and a transcriptional
terminator signal. Polyadenylation is not necessary as the
riboZyme is not translated.

Expression of a riboZyme Whose coding sequence has

sequences could remove premature stop codons, restore
altered reading frames, or remove insertion mutations that

tWo sequence preferences. The ?rst is a uridine at the 5'

provides transcriptional regulatory elements that control the
transcription of the riboZyme in the host cell. Such elements
may include, but not necessarily be limited to, a promoter

The applicability of trans-excision-splicing

sion region that is involved in a common form of Muscular

riboZymes used in the present invention contain at least tWo
modi?able REs. In a preferred embodiment, the riboZyme
conatins modi?ed RBI and RE3. Which alloWs the riboZyme
to target designated substrates at the level of simple base

Dystrophy in a small model system in vitro. Therefore,

pairing. Furthermore, the TES reactions using the R carinii

riboZymes to treat disease has been demonstrated by design
ing a riboZyme that speci?cally removes the triplet expan

65
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and Telrahymena riboZymes do not require a guanosine

uL). After an initial denaturation for 30 seconds at 95° C.,
the mixture Was subjected to 15 cycles of 95° C. for 30
seconds, 500 C. for tWo minutes, and 68° C. for six minutes.

cofactor, and optimally occur at a lower MgCl2 concentra

tion (7413 mM) and temperature (440 C.).
Sullenger and Cech ((1994) Nature 371, 6194622.) pre
viously reported that Telrahymena group I intron riboZymes

Parental plasmid Was then digested With 20 units Dpn I

that lack a 5' exon, but contain an endogenous non-native 3'

er’s supplied buffer for 2 hours at 37° C. 3 pL of this mixture

exon, catalyze the covalent attachment of the endogenous 3'

Was then used to transform E. coli DHSO. competent cells

(Gibco BRL; Rockville, Md.) in 5.7 pL of the manufactur

exon to mutant transcripts in such a Way as to replace the 3'

(Gibco BRL). The vectors Were puri?ed using a QIAprep

end of mutant transcripts With normal ‘corrected’ versions.

Spin Miniprep Kit (QIAGEN; Valencia, Calif.). The result

While trans-splicing can repair RNA, it exploits only the

ant ?nal plasmid, P-8/4x-MD, Was sequenced for con?rma

RE1 molecular interaction, the riboZymes must be
covalently attached to the repaired half of the transcript, it is
single-turnover, and repairing mutations distant from the 3'
end of long transcripts could be problematic. In contrast, the

tion (ACGT, Inc; Northbrook, Ill.). The plasmids Were
lineariZed With Xba I, phenol/chloroform extracted, and
ethanol precipitated in preparation for run-olf transcription.

TES reaction exploits multiple molecular interactions (RE1,
RE3, and perhaps RE2), TES riboZymes excise an internal

scribed from their appropriate plasmid precursors essentially
as previously described for rP-8/4x (Testa, S. M., Haidaris,
C. G., Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36,

Transcription. Both rP-8/4x and rP-8/4x-MD Were tran

segment from Within RNA substrates, the reaction is poten
tially multiple turnover, and the position of the mutations
Within the transcript is not a limiting factor. Moreover, that
under the conditions used in this report, little (if any)

15303415314). A typical transcription reaction (40 pL)
20

turnover Was observed.

EXAMPLE 1

0ligonucleotide synthesis and preparation. DNA oligo

25

MOPS (pH 7.0), 15% ethanol, and 0.15% Triton X-100).

nucleotide primers Were purchased from Integrated DNA
Technologies (Coralville, IoWa), and Were used Without
further puri?cation. RNA oligonucleotides Were purchased
from Dharmacon Research Inc. (Boulder, Colo.) and depro

tected folloWing the manufacturer’s protocol. The oligori

Second, the transcription reactions Were loaded onto the
column and the column Was Washed With 7.0 mL of Buffer

I. Third, the transcripts Were eluted using 4.0 mL of Buffer
30

electrophoresis as previously described (Testa, S. M., Hai
daris, C. G., Gigliotti, E, & Turner, D. H. (1997) Biochem
islry 36, 15303415314). The RNA products Were extracted

Trans-excision-splicing reactions. Reactions Were con

from the gel slice by stirring for one hour With a sterile
stir-bar in 1.5 mL elution buffer containing 10 mM Tris (pH
7.4), 250 mM NaCl, and 1 mM EDTA. Gel particulate Was
removed via centrifugation, and the solution Was evaporated
to a ?nal oligoribonucleotide concentration of approxi

35

mately 8 nM.
Plasmid construction and synthesis. The R carinii
riboZyme plasmid precursor, P-8/4x, Was generated as pre

40

each product Was obtained at 37° C. at both 7 and 13 mM

MgCl2 for each riboZyme (data not shoWn). Prior to each
reaction, 1.0 pmol of riboZyme in 5.0 pL of the appropriate
buffer Was preannealed at 60° C. for ?ve minutes and then
alloWed to sloW-cool to the appropriate temperature. Reac

sor, P-8/4x-MD, Was derived from the P-8!4x plasmid by

tions using the rP-8/4x riboZyme Were initiated by adding

of mutagenesis Were performed to modify each of the three

1.0 pL of 8 nM radiolabeled 36-mer, 12-mer, or 10-mer R
50

ments as compared to P-8/4x)1 5' CACGCCGCTTTC

GGGAACCTCTATAGTGAGTCG3v (SEQ ID N011) and 5'
CGACTCACTATAGAGGTTCCCGAAAGCGGCGTG3 '

55

and

then

5'

carinii substrate. The substrate sequences and hoW they base
pair With the riboZymes are shoWn in FIG. 2. In each case the
in the ?gures). After one hour, the reactions Were terminated

CGACTCACTATA

by adding an equal volume of stop buffer (10 M urea, 3 mM
EDTA, and 0.1><TBE). The products and reactants Were

@GTTCCCGAAAGCGGC3v (SEQ ID N015) and 5'

GCCGCTTTCGGGAACACCTATAGTGAGTCG3v (SEQ
ID N016) for RE3 formation.

carini-speci?c substrates or the 38-mer Myotonic Dystrophy
substrate. Reactions using the rP-8/4x-MD riboZyme Were
initiated by adding 1.0 pL of 8 nM radiolabeled 38-mer
Myotonic Dystrophy-speci?c substrate or the 36-mer R
substrates Were preincubated in the appropriate buffer (listed

GAAAGAGGQAGACTATACC3v for RE2 (SEQ ID
formation,

MgCl2 concentration range of0 to 50 mM at 30° C., 37° C.,
and 44° C. Maximum product formation occurred at 44° C.

for both riboZymes, 7 mM MgCl2 for rP-8/4x, and 13 mM
MgCl2 for rP-8/4x-MD, although a signi?cant amount of

site-directed mutagenesis. Brie?y, three successive rounds

N014)

ducted in HxMg buffer consisting of 50 mM Hepes (25 mM
Na’’), 135 mM KCl, and ><mM MgCl2 (listed in the ?gures)
at pH 7.5. The trans-excision-splicing reactions Were opti
miZed for the rP-8/4x and rP-8/4x-MD riboZymes over a

viously described (Testa, S. M., Haidaris, C. G., Gigliotti, E,
& Turner, D. H. (1997) Biochemistry 36, 153034153 14).
The Myotonic Dystrophy-speci?c riboZyme plasmid precur

(SEQ ID N012) for RE1 formation, 5' GGTATAGTCT
mCCTCTTTCGAAAG3v (SEQ ID N013) and 5' CTTTC

II (1.0 M NaCl, 50 mM MOPS (pH 7.0), and 15% ethanol).
Following an isopropanol and then an ethanol precipitation,
the samples Were dissolved in Water and quanti?ed using a
Beckman UV-VIS DU-650 spectrophotometer.

bonucleotides Were 5' end radiolabeled and puri?ed via gel

recognition elements using the folloWing pairs of mutagenic
primers (underlined bases represent altered recognition ele

contained 1 pg lineariZed plasmid, 40 mM Tris-HCl (pH
7.4), 5 mM dithiothreitol, 5 mM spermidine, 5 mM MgCl2,
1.5 mM each NTP, 1.25 mg/mL BSA, and 4 pL of T7 RNA
polymerase (100 units/uL) and Was incubated for tWo hours
at 37° C. The resultant RNA Was puri?ed using QIAGEN-tip
100 anion-exchange columns. First, each column Was equili
brated With 4.0 mL of Bulfer I (750 mM NaCl, 50 mM

60

denatured for one minute at 90° C. and then separated on a

12% acrylamide/8 M urea gel. The gel Was transferred to

Each set of primers (15 pmol each primer) Was used in an

chromatography paper (Whatman 3MM CHR) and dried

ampli?cation reaction comprising 25 ng parental plasmid,
2.5 units Pfu DNA polymerase (Stratagene; La Jolla, Calif.),

under vacuum. The bands Were visualiZed and quanti?ed on

and 0.5 uM dNTPs in a buffer comprising 10 mM KCl, 10

mM (NH4)2S04, 20 mM Tris-HCl (pH 8.8), 2 mM MgS04,
0.1% Triton X-100, and 0.1 mg/mL BSA (?nal volume 50

a Molecular Dynamics Storm 860 Phosphorimager.
65

The observed rate constant, kobs, for the ?rst (5' cleavage)
and second (exon ligation) step of each reaction Was quan
ti?ed (Testa, S. M., GryaZnov, S. M. & Turner, D. H. (1998)
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Biochemistry 37, 937949385; Mahadevan, M., Tsil?dis, C.,
Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville,

tWo-step trans-excision-splicing reaction (5' cleavage), and
indicates that a portion of the transcript undergoes only the

C., Narang, M., Barcelo, 1., O’Hoy, K., et al (1992) Science

?rst step of the reaction. Also produced is a small amount of

255, 12534125). The ?rst step Was obtained from a plot of
the percent intermediate plus percent product formed versus
time, and the second step Was obtained from a plot of percent

riboZyme mediated 3' splice site hydrolysis product at 26
nucleotides. Nonetheless, the rP-8/ 4x riboZyme contains the

product formed versus time. These observed rate constants

splicing reaction.

re?ect the rate of chemistry and any requisite conformation

Apparently, a majority of the 36-mer substrate undergoes
only the ?rst step of the reaction. The dependence of the TES
reaction on MgCl2 concentration, time, and rP-8/4x concen
tration is shoWn in FIG. 3B. The kobs for the ?rst and second
step of the reaction are 1.69 and 0.05 min-1, respectively.
The reaction is complete after 40 minutes and only requires
20 nM riboZyme for maximal activity (With 1.33 nM sub
strate). These results shoW that the rP-8/4x riboZyme, in the
absence of a nucleotide cofactor, inherently contains the

ability to bind a substrate in trans and catalyZe the excision

changes that occur.

Sequencing the trans-excision-splicing products. Products
obtained from the trans-excision-splicing reactions Were gel

puri?ed and sequenced by partial nuclease digestion using
T1 (Epicentre; Madison, Wis.), U2 (Research Unlimited;
Wellington, NeW Zealand), and Cl-3 (Research Unlimited)
RNA nucleases. T1 reactions used 1.0><10_4 units T1 in 200
mM Tris-HCl (pH 7.5), Cl-3 reactions used 0.33 units Cl-3
in 200 mM Tris-HCl (pH 7.5), and U2 reactions used 0.33
units U2 in 200 mM Tris-HCl (pH 3.5). Sequencing reac
tions utiliZed approximately 50 fmol of RNA and Were
incubated for 10 minutes at 55° C. Immediately after adding

ability to bind a substrate in trans and catalyZe the TES
reaction.
Even though there are 18 other uridines that could be sites

Were loaded on a 13.5% polyacrylamide/8 M urea gel. In

of 5' cleavage and four other guanosines that could be sites
of 3' splicing for the 36-mer substrate, only the expected
TES product is generated. Apparently, the riboZyme recog

parallel With the above reactions, We enZymatically

nition elements that de?ne the individual catalytic steps are

20

an equal volume of stop buffer to each reaction, aliquots

sequenced chemically synthesiZed versions of the expected
trans-excision-splicing products for comparison.

25

To determine if the 3' product of the ?rst reaction step (5'

cleavage) (FIG. 1B) is dissociating and then rebinding the

or at least signi?cantly hinder the required conformational
rearrangement betWeen the tWo catalytic steps. One or both

same (or different) riboZyme before the second reaction step
(exon ligation), TES reactions Were conducted for one hour

in 7 mM MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM
radiolabeled 36-mer substrate, and either 66.5 nM (50><) or

30

of these might account for the majority (>50%) of the
36-mer substrate only undergoing the ?rst catalytic step, in
contrast to less than 10% only undergoing the ?rst step for
the self-splicing reaction in vitro (15, 17). The lack of
product breakdown seen in the time dependence studies,

35

hoWever, indicates that the TES products themselves are not

665 nM (500><) 3' exon mimic competitor r(GUGCUCU)
(SEQ ID NO:16). The values reported are the average of six
independent assays. Likewise, to determine if the 5' product

of the ?rst reaction step (5' cleavage) (FIG. 1B) is dissoci
ating and then rebinding the riboZyme before the second step

substrates for further reactions, although guanosine depen
dent 5' cleavage or riboZyme-mediated hydrolysis of the

(exon ligation), TES reactions Were conducted for one hr in
7 mM MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM 36-mer
non-radiolabeled substrate, and 1.33 nM radiolabeled 5'

exon mimic competitor r(AUGACU) (SEQ ID NO:15). In

sequence speci?c. That the riboZyme can catalyZe this
reaction at all is surprising in that the relatively long
bridging region could be expected to sterically hinder the
binding of the substrate to the catalytic core of the riboZyme,

products could be a factor in vivo.
40

each case the competitors Were added simultaneously With
the substrates.

Previous studies utiliZing the rP-8/4x riboZyme (Testa, S.
M., GryaZnov, S. M. & Turner, D. H. (1998) Biochemistry
37, 937949385) shoW that the 5' exon mimic r(AUGACU)

(SEQ ID NO:15) binds to the rP-8/4x riboZyme (Kd:5.2 nM
at 37° C.) three orders of magnitude more tightly than the 3'

EXAMPLE 2
45

exon mimic r(GUGCUCU) (SEQ ID NO:16) (Kdz20 uM at
37° C.). Interestingly, maximum TES product formation

The R carinii group I intron riboZyme catalyZes the

occurs With as little as 20 nM riboZyme (at 44 ° C.),

trans-excision-splicing reaction. In order to test Whether a

indicating that for ?nal product formation the 5' and 3' exon

riboZyme derived from a group I intron, and speci?cally one
from R carinii, catalyZes the trans-excision-splicing reac
tion, a substrate Was designed that Would bind the rP-8/4x

intermediates produced during the 5' cleavage step might not
50

riboZyme’s native recognition element sequences (RE1,
RE2, and RE3 in FIG. 1b). These substrate sequences Were
connected With a bridge consisting of the ?rst four bases of
the intron and 13 uridines (FIG. 2A). Uridines Where chosen
because of their relatively poor ability to form self-structures
and the number of uridines (13) Was chosen arbitrarily.
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dissociate and then rebind the riboZyme before the exon
ligation step. To test for 5' exon dissociation and rebinding
betWeen the tWo steps, TES reactions Were conducted With
166 nM rP-8/4x, 1.33 nM non-radiolableled 36-mer, and
1.33 nM radiolabeled 5' exon, r(AUGACU) (SEQ ID
NO:15). In this case, if the 5' exon intermediate dissociates
from the riboZyme, the radiolabeled 5' exon is just as likely
to then bind the riboZyme and form the 16-mer product as

Typical results at the optimiZed MgCl2 concentration (7

the non-radiolabeled 5' exon intermediate. As seen in FIG. 5,

mM) and the temperature (440 C.) are shoWn in FIG. 3A.
The expected product band at 16 nucleotides in length

no radiolabeled TES products are observed, indicating the 5'
exon intermediate does not dissociate from the riboZyme
betWeen the tWo steps (for those 5' exon intermediates that

Was obtained in a yield of 25%:5% (for 6 independently run
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undergo the complete reaction).

assays). This band Was extracted from the gel matrix,

repuri?ed, and subjected to enzymatic sequencing, along

LikeWise, to test for 3' exon intermediate dissociation and

With a chemically synthesiZed version of the expected
product. The sequence and banding patterns Were identical

rebinding betWeen the tWo reaction steps, TES reactions

(FIG. 4), indicating that the expected trans-excision-splicing
product Was generating. The reaction also produced a band
at six nucleotides. This is a product of the ?rst step of the

Were conducted With 166 nM rP-8/ 4x, 1.33 nM radiolabeled
65

36-mer, and a 50 (66.5 nM) or 500 (665 nM) fold excess of
a

non-radiolabeled

3'

exon

mimic

competitor,

r(GUGCUCU) (SEQ ID NO:16) Which Would form a

US 7,211,661 B2
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10-mer competition product. At equal molar concentrations

effect is unknown, but could be due to the reduced steric
hindrance of the smaller bridge on the required conforma
tional rearrangement betWeen the tWo reaction steps. This
could re?ect an increased af?nity or accessibility of the 3'

if the 3' exon intermediate dissociates from the riboZyme, the
7-mer competitor is 2.5 times more likely to bind the
riboZyme and be a substrate in the second reaction step than
the 30-mer 3' exon intermediate (data not shoWn). The
results (FIG. 5) shoW that a 500-fold excess of cold com
petitor over substrate does not signi?cantly reduce the
amount of 16-mer product formed (19.4%:2.3% versus
22.8%:3%, respectively). The small amount of 10-mer
product that is observed at 500-fold excess competitor over

guanosine of the bridge for the G-binding site of the

riboZyme. Indeed, previous reports suggest that the ability of
the G-binding site to bind this endogenous guanosine drives
the second step of the reaction (Mahadevan, M., Tsil?dis, C.,

Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville,
C., Narang, M., Barcelo, 1., O’Hoy, K., et al (1992) Science
255, 125341255; Harley, H. G., Rundle, S. A., MacMillan,
1. C., Myring, 1., Brook, 1. D., CroW, S., Reardon, W.,

substrate (but not 50-fold excess) is not actually competing
With the TES reaction. In these cases, the riboZymes that
have bound radiolabeled 5' exon regions, and for Which the
3' exon region has dissociated, are binding and reacting With

Fenton, 1., Shaw, D. 1., & Harper, P. S. (1993) Am. J. Hum.

Genet. 52, 116441174).

a small amount of the huge excess of 3' exon competitor.

EXAMPLE 4

Therefore, the vast majority of substrates that undergo the
complete TES reaction do not have 3' exon intermediate

dissociation and rebinding occurring betWeen the tWo steps
of the reaction. Apparently, substrates that undergo only the
?rst reaction step do so because of nearly irreversible 5' or
3' exon intermediate dissociation. It folloWs that since

20

sequences. Therefore, a truncated DMPK mimic model

system Was developed (FIG. 2Biii) for analyZing the ability

intermediates to the complete TES reaction do not dissociate
from the riboZyme, the TES reaction is intramolecular With

of a re-engineered riboZyme to excise the RNA triplet repeat
region Whose expansion is the causative agent of the effects

regard to substrate.
25

EXAMPLE 3

Excision of a single nucleotide using the R carinii.
riboZyme. In order to determine if a loWer limit exists to the
length of the excised region, We tested the TES reaction
using the rP-8/4x riboZyme With tWo neW substrates. One

substrate is a 12-mer, r(AUGACUGUGCUC) (SEQ ID
NO:7), and Was designed to contain the minimum length
bridging sequence that could utiliZe the 2 base pair RE2
interaction (to form the P90 helix) and the 3' guanosine
thought to be required for self-splicing (FIG. 2Bi). The other
substrate is a 10-mer, r(AIKLACllGClLC) (SEQ ID NO:8),

30

of TES products), the ?rst guanosine doWnstream from the
?ve successive guanosines Was targeted. The substrate
bridge contained 5 CUG repeats, as this is the smallest

number of repeats thought to form the hairpin structure
similar to that seen With the expanded transcripts. Myotonic
Dystrophy patients actually have greater than 15 CUG
35

repeats. Nevertheless, the riboZyme targets the ?anking
regions and Would be the same regardless of the number of
triplet repeats. This riboZyme is referred to as the rP-8/4x
MD riboZyme and this substrate the 38-mer DMPK mimic.

The results at the optimum MgCl2 concentration (13 mM)
40

10 mM MgCl2 and 440 C., both the 12-mer and 10-mer
reactions lead to the formation of the expected 9-mer

products, as con?rmed by enZymatic sequencing (data not
shoWn). The optimiZed reactions produce 72%:3.9% prod
uct for the 12-mer substrate and 69.3%:4.4% product for the

of the genetic disease, Myotonic Dystrophy. AriboZyme Was
designed to target the uridine immediately upstream of the
repeats. Because there are ?ve successive guanosines imme
diately folloWing the repeats (Which could lead to a mixture

Which can not utiliZe the RE2 interaction, and from Which

only one nucleotide Would be excised (FIG. 2Bii). The
results (FIG. 3A) shoW that, under the optimal conditions of

The sequence speci?city of the R carinii riboZyme can be
altered. For the TES reaction to be useful, the recognition
elements must be mutable in order to target predetermined

45

and temperature (440 C.) are shoWn in FIG. 6A. A 10
nucleotide product Was obtained, as expected, in a yield of
61.1%:4.6% (for 6 independently run assays). Besides
unreacted 6-mer generated from the ?rst step of the reaction,
no other products are produced to any signi?cant amount,

indicating a reasonably speci?c reaction. The 10-mer prod

rP-8/4x riboZyme can excise as little as a single nucleotide.

uct Was extracted from the gel and enZymatically sequenced,
along With a chemically synthesiZed version of the expected

The same approximate yield is obtained using the 12-mer
and 10-mer substrates Which suggests that the role of
forming the P90 helix is not large in this case. Therefore, the

product. The sequence and banding patterns obtained (FIG.
4) shoW that the expected TES product is being generated.
Apparently, the riboZyme can be modi?ed (at RE1, RE2, and

10-mer substrate (for 6 independently run assays). Thus, the

50

RE3) to target non-native substrates. The dependence of this
reaction on MgCl2 concentration, time, and rP-8/4x-MD
concentration is shoWn in FIG. 6B. The kobs for the ?rst and

RE2 interaction, although perhaps bene?cial, is not required
for sequence speci?c TES reactions. In addition, the 12-mer
and 10-mer substrates lead to more than tWice the product as

compared With the 36-mer substrate, implicating the longer
bridging region (Which includes the four 5' bases of the

55

intron) as being detrimental for this reaction. As the amount
of substrate that undergoes at least the ?rst reaction step is
similar for all of the different substrates, 3' exon intermediate
dissociation for the 36-mer likely accounts for the difference
in extent of ?nal product formation. The dependence of the
10-mer substrate reaction on MgCl2 concentration, time, and
rP-8/4x concentration is shoWn in FIG. 3C. The kobs for the
?rst and second step of the reaction are 4.12 and 2.89 min-l,
respectively. In contrast to that for the 36-mer, the reaction

60

With the 10-mer substrate is more favorable at MgCl2

65

concentrations greater than 7 mM, and the second reaction
step occurs approximately 50-fold faster. The origin of this

second step of the reaction are 0.41 and 0.44 min-l, respec
tively (note that these values are Within experimental error
and the rate of the second step is likely limited by the rate
of the ?rst step). Interestingly, the excision of this 28-mer

bridge, Which could include a triplet repeat hairpin structure,
is substantially more effective than the 36-mer rP-8/4x
system, Which excises a 20-mer unstructured bridge. Thus,

targets With large bridge regions are not necessarily poor
reaction substrates.

To determine Whether each riboZyme has speci?city for
its intended target, TES reactions Were run using the rP-8/
4x-MD riboZyme With the 36-mer R carinii substrate at 13

mM MgCl2, and the rP-8/4x riboZyme With the 38-mer
DMPK mimic at 7 mM MgCl2, each at 440 C. (FIG. 6A). In

US 7,211,661 B2
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addition, the reaction Was run using the rP-8/4x-MD

the ?rst step of the self-splicing reaction (14, 20, 21), it Was

riboZyme at 7 mM MgCl2 and another reaction using the

previously not knoWn that all three recognition elements are

rP-8/4x riboZyme Was run at at 13 mM MgCl2 (data not

modi?able. That these recognition elements completely
specify binding and reactivity indicates that they are the
primary determinants of speci?city betWeen the riboZyme
and its substrate. In addition, bridging regions of di?cerent
sequences and lengths (l, 3, 20, and 28 nucleotides) have
been excised, indicating that perhaps a 3' G in the bridging
region might be the only sequence requirement for the
excised segment.

shoWn). In these reactions, not even 5' cleavage products are

observed, indicating that the riboZymes have some speci?c
ity for their intended target substrates. Although the MgCl2
concentration required for maximum activity di?cers for all
the reactions, they all occur at or beloW that required (15
mM) for maximum activity for the R carinii group I intron
self-splicing reaction in vitro. While it Was knoWn that the
sequence of REl could be modi?ed in reactions mimicking

SEQUENCE LISTING

SEQ ID NO 1
LENGTH: 33
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
FEATURE:

NAME/KEY: miscifeature
LOCATION:

(13) .. (18)

OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4x
<400> SEQUENCE: l

cacgccgctt tcgggaacct ctatagtgag tcg

33

<2 10> SEQ ID NO 2
<2ll> LENGTH: 33
<2 12> TYPE: DNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222> LOCATION: (15)..(21)
<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4x
<400> SEQUENCE: 2

cgactcacta tagaggttcc cgaaagcggc gtg

33

<2 10> SEQ ID NO 3
<2ll> LENGTH: 25
<2 12> TYPE: DNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222> LOCATION: (11)..(12)
<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4x
<400> SEQUENCE: 3

ggtatagtct tgcctctttc gaaag

SEQ ID NO 4
LENGTH: 25
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
FEATURE:

NAME/KEY: miscifeature

25
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-continued

<222> LOCATION:

( 14 ) . . ( 15 )

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4x
<400> SEQUENCE: 4

ctttcgaaag aggcaagact atacc

25

<2 10> SEQ ID NO 5
<2ll> LENGTH:

30

<2 12> TYPE: DNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222> LOCATION:

( 13 ) . . ( 15 )

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4x
<400> SEQUENCE: 5

cgactcacta taggtgttcc cgaaagcggc

30

<2 10> SEQ ID NO 6
<2ll> LENGTH: 30
<2 12> TYPE: DNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<220> FEATURE:

<22l> NAME/KEY: miscifeature
<222> LOCATION:

( l6 ) . . ( l8 )

<223> OTHER INFORMATION: Represent altered recognition elements as

compared to P-8/4x
<400> SEQUENCE: 6

gccgctttcg ggaacaccta tagtgagtcg

30

<2 10> SEQ ID NO 7
<2ll> LENGTH:

12

<2 12> TYPE: RNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 7
augacugugc uc

l2

<2 10> SEQ ID NO 8
<2ll> LENGTH:

10

<2 12> TYPE: RNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chenically synthesized
<400> SEQUENCE: 8
augacugcuc

l0
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6. The riboZyme of claim 5 Wherein the riboZyme
removes the triplet expansion region involved in Muscular

What is claimed is:

1. A modi?ed trans-excision-splicing Group I riboZyme
comprising at least tWo modi?able recognition elements,

Dystrophy.

Wherein at least one of said recognition elements is comple
mentary to non-native target RNA sequence Within a sub

recognition elements stabilizes binding of the riboZyme to a

7. The riboZyme of claim 1 Wherein the riboZyme is a
modi?ed R carinii riboZyme.
8. An expression cassette comprising a promoter oper

trans-excision splicing (TES) reaction intermediate product,

ably-linked to a nucleotide sequence encoding a trans

strate having a 5' and 3' end and at least one of said

and Wherein the riboZyme initiates a ?rst catalytic step in the
absence of a guanosine cofactor and catalyZes a sequence
speci?c excision of the non-native target RNA sequence,
thereby forming a ?rst intermediate comprising the 5' end of
the substrate and a second intermediate comprising the 3'
end of the substrate, each intermediate having a 5' and 3' end,
and splices the 3' end of the ?rst intermediate to the
guanosine of the 5' end of the second intermediate created by
the excision.
2. The riboZyme of claim 1 Wherein the non-native target
sequence is a single nucleotide.
3. The riboZyme of claim 1 Wherein the non-native

excision-splicing Group 1 riboZyme comprising at least tWo
modi?able recognition elements, Wherein at least one of said

recognition elements is complementary to non-native target
RNA sequence Within a substrate and at least one of said

recognition elements stabiliZes binding of the riboZyme to a

trans-excision splicing (TES) reaction intermediate product,
and Wherein the riboZyme initiates a ?rst catalytic step in the
absence of a guanosine cofactor and catalyZes a sequence

speci?c excision of the non-native target RNA sequence,
thereby forming a ?rst intermediate comprising the 5' end of
20

sequence comprises a premature stop codon.
4. The riboZyme of claim 1 Wherein the non-native

and splices the 3' end of the ?rst intermediate created by the
excision to the guanosine of the 5' end of the second

sequence comprises a frameshift mutation.
5. The riboZyme of claim 1 Wherein the at least one

recognition element is complementary to the triplet expan
sion associated With Muscular Dystrophy.

the substrate and a second intermediate comprising the 3'
end of the substrate, each intermediate having a 5' and 3' end

intermediate created by the excision.
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